

United European Gastroenterology Week October 28 - November 1, 2017 Barcelona, Spain



# Endoscopic Application of Mucoadhesive Powder (Nexpowder™) For Hemostasis In Patients With Gastrointestinal Bleeding

ByoungWook Bang<sup>1</sup>, Kye Sook Kwon<sup>1</sup>, Hyung Kil Kim<sup>1</sup>, Yong Woon Shin<sup>1</sup>, Su Jin Hong<sup>2</sup>, Jae Jin Hwang<sup>2</sup>, Jong Ho Moon<sup>2</sup>

<sup>1</sup>Division of Gastroenterology, Department of Internal Medicine, Inha University School of Medicine, Incheon Republic of Korea

<sup>2</sup>Digestive Disease Center and Research Institute, Department of Internal Medicine, Soon Chun Hyang University School of Medicine, Bucheon


## Introduction:

Endoscopic hemostasis is often challenging, depending on location, extent and features of bleeding. We have developed a new hemostatic adhesive drug loadable powder (Nexpowder ™ ) that can be used endoscopically

# Aims & Methods:


- Prospective study investigating the efficacy of Nexpowder™ in patients with various gastrointestinal bleeding.
- The Nexpowder was applied to post-ESD/EMR ulcer or to the bleeding sites undergoing insufficient hemostasis.
- Aims of this study
- 1) the success rate of hemostasis
- 2) re-bleeding rate on second-look endoscopy at the next day
- 3) Persistent rate of Nexpowder™ on ulcer base at follow-up endoscopy
- 4) clogging rate of spraying catheter during applying Nexpowder™.

Fig 1. Characteristic of Nexpowder™



Nexpowder consists of oxidized dextran and succinic acid modified amino acid. It is biodegradable and biocompatible. Powder forms the highly adhesive gel after contacting the water or blood

Fig 2. Composition of Nexpowder®



Nexpowder system consist of gun (A), catheter (B) and powder (C)

	NEXPOW DER	Hemosp ray <sup>®</sup>	Endoclot ®
Shape	Granule	Granule	Powder
Clotting cascade	Unrelated	Activate	Activate
Gelation	0	Х	Δ
Degradati on time ( <i>in vivo</i> )	24~72h	Less than few hours	Less than few hours

### **Results:**

A total of 57 patients were enrolled. The bleeding developed in 46 patients with postendoscopic resection ulcers (41 ESD induced ulcers and 5 EMR induced ulcers), 8 patients with peptic ulcers and 3 patients with miscellaneous bleeding.

**Table 2. Demographic date** 

Age	64.6 ± 11.2 years (Mean ± SD)
Sex	M:F = 44: 13
Reason of bleeding	Post ESD/EMR bleeding : 46 Peptic ulcer bleeding : 8 Others (AGC, Colon ESD, Jejunal ulcer) : 3

**Table 2. Success Rate of Hemostasis** 

Etiology of Bleeding	Success Rate, %
Peptic ulcer (Stomach & Duodenum)	100 (8/8)
Endoscopic resection	97.8 (45/46)
G-EMR	100 (5/5)
G-ESD	97.5 (39/40)
D-EMR	100 (1/1)
Advanced gastric cancer (AGC)	100 (1/1)
Jejunal ulcer and liver cirrhosis	0 (0/1)
Colon ulcer	100 (1/1)
Total	96.5 (55/57)

Fig 3. Persistent Rate of Nexpowder





70.3% (26/57) at 1 day 38.5% (15/38) at 3 day

After the procedure

A: After spraying

B : One day later


C: Three days later


Nexpower

Clogging rate of spraying catheter was 4.4% (2/45).

**Table 3. Rebleeding rate: 5.3% (3/57)** 

Case	Etiology of Bleeding	Development Time of Re- bleeding
1	Post-ESD (EGC)	1 day later
2	Post-ESD (EGC)	1 day later
3	Jejunal ulcer, Liver Cirrhosis	3 days later





# Summary

- 1) Success rates of hemostasis in acute bleeding were 96.5% (55/57)
- 2) Re-bleeding rates were 5.3% (3/57)
- Persistent rate of Nexpowder on ulcer base was 70.2% (26/37) 1 day after the procedure, and 38.4% (15/38) 3 days after the procedure
- 4) Clogging rate of spraying catheter was 4.4% (2/45).

#### **Conclusions:**

- 1. The endoscopic application of Nexpowder is effective for the acute GI bleeding.
- 2. The hemostatic action of Nexpowder appears to be from high mucoadhesiveness and hydrogel persistence.
- 3. The new powder delivering device shows low rate of catheter clogging and targeted spraying properties onto bleeding site